



CSL Seqirus Portfolio Coding and Billing Guide

2023-2024

Please see Important Safety Information on pages 11-13 and accompanying full US Prescribing Information for each product.

For US Healthcare Professional Use Only

Find more resources at flu360.com

CSL Seqirus

Using this guide

Consider this your go-to comprehensive resource for all 3 quadrivalent influenza vaccines to ensure the use of appropriate CPT codes, check recent NDCs, code appropriately based on payer, and more. You can also find individual vaccine guides at flu360.com. When it comes to coding and billing for CSL Seqirus vaccines, we've got you covered.

3 Code for the CSL Seqirus vaccine administered

4 Current NDCs

5 Code for the administration service

6 FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted)

7 FLUCELVAX® QUADRIVALENT (Influenza Vaccine)

8 AFLURIA® QUADRIVALENT (Influenza Vaccine)

9 Commonly asked questions

CPT=Current Procedural Terminology
NDCs=National Drug Codes

Code for the CSL Seqirus vaccine administered

CPT codes indicate the influenza vaccine administered. Be sure to use the appropriate CPT code to receive proper payment.

FLUAD QUADRIVALENT, the first and only adjuvanted quadrivalent seasonal influenza vaccine for adults 65 years and older, uses CPT code 90694.^{1,2}

FLUCELVAX QUADRIVALENT, an innovative cell-based vaccine for people 6 months and older, has unique CPT codes 90674 and 90756.^{1,3}

CSL Seqirus Vaccine Product Description	Presentation/ Dose	Age Indication	Vaccine Product CPT Code	2023-2024 NDC Carton	2023-2024 NDC Unit-of-Use	CVX Code*	MVX Code
FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted)	Pre-filled syringe 0.5 mL	65 years and older	90694	70461-123-03	70461-123-04	205	SEQ

90694=Influenza virus vaccine, quadrivalent (allV4), inactivated, adjuvanted, preservative free, 0.5-mL dosage, for intramuscular use

FLUCELVAX® QUADRIVALENT (Influenza Vaccine)	Pre-filled syringe 0.5 mL	6 months and older	90674	70461-323-03	70461-323-04	171	SEQ
	Multi-dose vial 5 mL	6 months and older	90756	70461-423-10	70461-423-11	186	SEQ

90674=Influenza virus vaccine, quadrivalent (cclIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5-mL dosage, for intramuscular use

90756=Influenza virus vaccine, quadrivalent (cclIV4), derived from cell cultures, subunit, antibiotic free, 0.5-mL dosage, for intramuscular use

AFLURIA® QUADRIVALENT (Influenza Vaccine)	Pre-filled syringe 0.5 mL	36 months and older	90686	33332-323-03	33332-323-04	150	SEQ
	Multi-dose vial† 5 mL	6 through 35 months	90687 (0.25-mL dose)	33332-423-10	33332-423-11	158	SEQ
		36 months and older	90688 (0.5-mL dose)				

90686=Influenza vaccine, quadrivalent (IIV4), split virus, preservative-free, 0.5-mL dosage, for intramuscular use

90687=Influenza vaccine, quadrivalent (IIV4), split virus, 0.25-mL dosage, for intramuscular use

90688=Influenza vaccine, quadrivalent (IIV4), split virus, 0.5-mL dosage, for intramuscular use

*CVX=vaccine administered code indicates which product was used and is used in combination with the manufacturer (MVX) code.

†The number of needle punctures should not exceed 20 per multi-dose vial.

National Drug Codes (NDCs) change each year for influenza vaccines

If your payer requires NDCs, confirm that you are using this year's NDCs, as they change each year for influenza vaccines. The NDCs for the 2023-2024 influenza season are listed in the grid to the left. TriCare, some Medicaid agencies, commercial payers, and Medicare Administrative Contractors (MACs) require the use of an 11-digit NDC in addition to the CPT code on claims for influenza vaccines (eg, FLUAD QUADRIVALENT-70461-0123-03; the red number shows where the additional zero needs to be added to make an 11-digit format and is the same for all of our vaccines). Note there are two different NDCs, carton or syringe/vial (unit-of-use), per the US Food and Drug Administration (FDA). Record the NDC on the syringe/vial (unit-of-use) in the patient's record, as per the standard procedure in your practice. Medicare, TriCare, and many commercial payers use the carton NDC for claims processing/reimbursement. For assistance with NDCs, call **flu360 Customer Service** at (855) 358-8966, option 2.

DISCLAIMER: The coding and billing information contained in this document is presented as a resource and guide to coding and billing for FLUAD QUADRIVALENT (Influenza Vaccine, Adjuvanted), FLUCELVAX QUADRIVALENT (Influenza Vaccine), and AFLURIA QUADRIVALENT (Influenza Vaccine). Coding and billing information is gathered from several sources and is subject to change without notice. While every effort is made to ensure the accuracy of this information, appropriate coding and billing for healthcare services are the provider's responsibility and should always be based on the patient's clinical condition, services provided, and payer guidelines.

Code for the administration service

The method of administration for CSL Seqirus vaccines should be reported in addition to the vaccine product code. Use the appropriate immunization administration code based on the service provided and documented in the medical record. The following CPT codes are for vaccines administered via injection to individuals.⁴

CPT Code	Description
90460	Immunization administration through 18 years of age via any route of administration with counseling by physician or other qualified healthcare professional; first or only component of each vaccine or toxoid administered
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)
90472	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)

Note: Medicare requires use of Healthcare Common Procedure Coding System (HCPCS) code G0008 for the preventive administration of an influenza vaccine. HCPCS code G0008 must be used when billing Medicare instead of the administration CPT codes, regardless of the patient age or provider counseling. Other payers may require the use of HCPCS G0008; check with your payer for preferred administration code.⁵

HCPCS Code	Description
G0008	Seasonal influenza virus vaccine administration

Influenza vaccine *International Classification of Diseases, Tenth Revision* diagnosis codes

Below is a suggested *International Classification of Diseases, Tenth Revision* (ICD-10) diagnosis code that may be appropriate when submitting claims for CSL Seqirus vaccines and their administration. The code should be linked to both the vaccine and administration codes.⁵

ICD-10 Code	Description
Z23	Encounter for immunization

Modifier 25 is used to denote when a patient receives a significant, separately identifiable Evaluation and Management (E/M) service by the same physician on the same day of the procedure or other service. The E/M service may be prompted by the symptom or condition for which the procedure and/or service was provided, so different diagnoses are not required for reporting the E/M services on the same date.

Note: This modifier is not used to report an E/M service that resulted in a decision to perform surgery; see modifier 57. For significant, separately identifiable, non-E/M services on the same day, see modifier 59.⁶

For any reimbursement-related questions, call flu360 Customer Service at (855) 358-8966, option 2.

Refer to the following pages for coding and billing information specific to CSL Seqirus vaccines.

Visit [flu360.com](https://www.flu360.com) for additional resources and information on coding and billing for CSL Seqirus flu vaccines

FLUAD[®] QUADRIVALENT (Influenza Vaccine, Adjuvanted) administered to a patient on Medicare

A 67-year-old man with Medicare is seen at an urgent care clinic after a fall. The physician recommends that he also receive an influenza vaccine and administers FLUAD QUADRIVALENT.^{1,2,5-7}

R29.6=repeated falls

Z23=encounter for immunization

If required by payer, 11-digit NDC format using the carton NDC. If payer requires NDC, use the “N4” qualifier immediately followed by the 11-digit carton NDC, followed by the qualifier “ML” for milliliter and the quantity as shown in the shaded area

Refer back to the appropriate diagnosis code on each line, including the vaccine and the vaccine administration

99203=office or other outpatient visit of 30-44 minutes for the E&M of a new patient

25=modifier (See page 5: Code for the administration service)

90694=FLUAD QUADRIVALENT

G0008=administration

Sample Claim Form

19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)											
21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY (Relate A-L to service line below (24E))										ICD Ind.	
A.	B.	C.	D.	E.	F.	G.	H.	I.	J.	K.	L.
R29.6	Z23										
24. A. DATE(S) OF SERVICE			B. PLACE OF SERVICE	C. EMG	D. PROCEDURES, SERVICES, OR SUPPLIES (Explain Unusual Circumstances)				E. DIAGNOSIS POINTER		
From	To				CPT/HCPCS	MODIFIER					
MM	DD	YY	MM	DD	YY						
N470461012303ML0.5											
09	15	23	09	15	23	11	99203	25		A	
09	15	23	09	15	23	11	90694			B	
09	15	23	09	15	23	11	G0008			B	

FLUCELVAX[®] QUADRIVALENT (Influenza Vaccine) administered at a problem-focused visit



A 34-year-old woman with a private health insurance plan is seen at the physician's office for evaluation of her asthmatic condition and related prescription refills. The physician recommends she receive an influenza vaccine and administers FLUCELVAX QUADRIVALENT.^{1,3,5-7}

Sample Claim Form

19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)

21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY Relate A-L to service line below (24E) ICD Ind.

A. **J45.40** B. **Z23** C. _____ D. _____
 E. _____ F. _____ G. _____ H. _____
 I. _____ J. _____ K. _____ L. _____

24. A. DATE(S) OF SERVICE B. PLACE OF SERVICE C. EMG D. PROCEDURES, SERVICES, OR SUPPLIES (Explain Unusual Circumstances) E. DIAGNOSIS POINTER

MM	DD	YY	MM	To	DD	YY		CPT/HCPCS	MODIFIER			
N470461032303MLO.5												
10	07	23	10	07	23	11		99212	25			A
10	07	23	10	07	23	11		90674				B
10	07	23	10	07	23	11		90471				B

J45.40=moderate persistent asthma, uncomplicated

Z23=encounter for immunization

If required by payer, 11-digit NDC format using the carton NDC. If payer requires NDC, use the "N4" qualifier immediately followed by the 11-digit carton NDC, followed by the qualifier "ML" for milliliter and the quantity as shown in the shaded area

Refer back to the appropriate diagnosis code on each line, including the vaccine and the vaccine administration

99212=office or other outpatient visit of 10-19 minutes for an established patient

25=modifier (See page 5: Code for the administration service)

90674=FLUCELVAX QUADRIVALENT

90471=administration

AFLURIA[®] QUADRIVALENT (Influenza Vaccine) administered at a well visit

A 28-year-old woman with a private health insurance plan is seen for a well visit and receives a needleless influenza vaccination, AFLURIA QUADRIVALENT.^{1,5-8}

Sample Claim Form

19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)

21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY Relate A-L to service line below (24E) ICD Ind

A. **Z00.00** B. **Z23** C. _____ D. _____
 E. _____ F. _____ G. _____ H. _____
 I. _____ J. _____ K. _____ L. _____

24. A. DATE(S) OF SERVICE						B. PLACE OF SERVICE	C. EMG	D. PROCEDURES, SERVICES, OR SUPPLIES (Explain Unusual Circumstances) CPT/HCPCS MODIFIER		E. DIAGNOSIS POINTER
From	To									
MM	DD	YY	MM	DD	YY					
N433332032303MLO.5										
09	25	23	09	25	23	11		99395	A	
09	25	23	09	25	23	11		90686	B	
09	25	23	09	25	23	11		90471	B	

Z00.00=encounter for general adult medical examination without abnormal findings

Z23=encounter for immunization

If required by payer, 11-digit NDC format using the carton NDC. If payer requires NDC, use the "N4" qualifier immediately followed by the 11-digit carton NDC, followed by the qualifier "ML" for milliliter and the quantity as shown in the shaded area

Refer back to the appropriate diagnosis code on each line, including the vaccine and the vaccine administration

99395=periodic comprehensive preventive medicine re-evaluation, established patient; 18-39 years

90686=AFLURIA QUADRIVALENT

90471=administration

Commonly asked questions

When it comes to coding and billing, accuracy matters.

Q: What is the age indication for FLUCELVAX® QUADRIVALENT (Influenza Vaccine)?

A: As of October 2021, FLUCELVAX QUADRIVALENT is approved for use in people 6 months of age and older.³ The billing CPT codes for FLUCELVAX QUADRIVALENT are as follows: CPT code 90674 (FLUCELVAX pre-filled syringe) and 90756 (FLUCELVAX multi-dose vial).¹

Q: What has changed with the CDC Advisory Committee on Immunization Practices (ACIP) and influenza vaccine recommendations for adults 65 years and older?

A: In June 2022, the ACIP voted 15-0 in favor of recommending specific influenza vaccines for adults 65+.⁹

The ACIP preferentially recommends adjuvanted or higher dose over standard-dose influenza vaccines.⁹

FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted) is included as a preferentially recommended seasonal influenza vaccine for adults 65 years and older.⁹

AWP=Average Wholesale Price
CMS=Centers for Medicare & Medicaid Services

Q: When will we know the Medicare reimbursement rates for the influenza vaccines for the next season? Where can I find the information?

A: The Medicare Part B payment allowances for seasonal influenza vaccines provided in the physician's office or clinic are based on 95% of the AWP as reflected in the published pricing compendia each year. You can locate this information by going to CMS.gov and typing "seasonal influenza vaccine reimbursement" into the search bar. All influenza vaccines will be listed on the CMS Medicare Fee for Service Vaccine pricing list by CPT code. Each flu season, CMS publishes the revised Medicare Part B fee for service vaccine pricing list for the flu season, typically by September of each year.¹⁰

Q: Where can I find Medicare's Part B Influenza Administration Rates for my locality?

A: To see your specific locality payment rate when billing for influenza vaccine administration (HCPCS G0008) visit "Seasonal Influenza Vaccines Pricing" on CMS.gov and download the 2023 Locality-Adjusted Rates for Influenza file.^{10,11}

Commonly asked questions

(continued)

Q: Which NDC should I use, the one on the box or the one on the actual vial of vaccine?

A: Most, but not all, payers require an NDC number on an influenza vaccine claim. Most commercial payers, TriCare, and some state Medicaid agencies require the carton NDC for claims processing/reimbursement. If you are not sure, check with your payer to confirm their preferred NDC, either carton or unit-of-use. If you need assistance, call **flu360 Customer Service** at (855) 358-8966, option 2.

Q: When a pharmacy is submitting a prescription claim for an influenza vaccine to the pharmacy benefit using the National Council for Prescription Drug Program (NCPDP) standard, what should a pharmacy submit in the Days Supply field?

A: When billing for a vaccine, it is recommended that the dispenser submit a value of 1 in the Days Supply field.¹²

Q: When a pharmacy is submitting a prescription claim for an influenza vaccine to the pharmacy using the NCPDP standard, what additional steps need to be taken to account for the administration portion?

A: Pharmacies should submit an “MA” (Medication Administered) in the Professional Service Code (440-E5) and submit an amount in the Incentive Amount Submitted (438-E3) to request reimbursement for the administration of an influenza vaccine.¹²

Q: What reimbursement services are offered via flu360 Customer Service?

A: We assist healthcare providers in understanding the coding, coverage, and reimbursement requirements for all of CSL Seqirus’ influenza vaccines. This includes verifying a patient’s insurance benefits, confirming payer requirements for coding, and, if needed, claims appeal support in the event of denied or underpaid claims.

DISCLAIMER: The coding and billing information contained in this document is presented as a resource and guide to coding and billing for FLUAD QUADRIVALENT (Influenza Vaccine, Adjuvanted), FLUCELVAX QUADRIVALENT (Influenza Vaccine), and AFLURIA QUADRIVALENT (Influenza Vaccine). Coding and billing information is gathered from several sources and is subject to change without notice. While every effort is made to ensure the accuracy of this information, appropriate coding and billing for healthcare services are the provider’s responsibility and should always be based on the patient’s clinical condition, services provided, and payer guidelines.

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE

FLUAD QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and types B contained in the vaccine. FLUAD QUADRIVALENT is approved for use in persons 65 years of age and older.

This indication is approved under accelerated approval based on the immune response elicited by FLUAD QUADRIVALENT. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Severe allergic reaction to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine.

WARNINGS AND PRECAUTIONS

If Guillain-Barré Syndrome (GBS) has occurred within six weeks of previous influenza vaccination, the decision to give FLUAD QUADRIVALENT should be based on careful consideration of the potential benefits and risks.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.

Syncope (fainting) may occur in association with administration of injectable vaccines including FLUAD QUADRIVALENT. Ensure procedures are in place to avoid injury from falling associated with syncope.

The immune response to FLUAD QUADRIVALENT in immunocompromised persons, including individuals receiving immunosuppressive therapy, may be lower than in immunocompetent individuals.

Vaccination with FLUAD QUADRIVALENT may not protect all vaccine recipients against influenza disease.

ADVERSE REACTIONS

The most common ($\geq 10\%$) local and systemic reactions in elderly subjects 65 years of age and older were injection site pain (16.3%), headache (10.8%) and fatigue (10.5%). Other adverse events may occur.

To report SUSPECTED ADVERSE REACTIONS, contact CSL Seqirus at 1-855-358-8966 or VAERS at 1-800-822-7967 and www.vaers.hhs.gov.

Before administration, please see the full Prescribing Information for FLUAD QUADRIVALENT [here](#).

FLUAD[®] QUADRIVALENT is a registered trademark of Seqirus UK Limited or its affiliates.

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION AND USAGE

FLUCELVAX QUADRIVALENT is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and types B contained in the vaccine. FLUCELVAX QUADRIVALENT is approved for use in persons 6 months of age and older.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Do not administer FLUCELVAX QUADRIVALENT to anyone with a history of severe allergic reactions (e.g. anaphylaxis) to any component of the vaccine.

WARNINGS AND PRECAUTIONS

If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLUCELVAX QUADRIVALENT should be based on careful consideration of the potential benefits and risks.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.

Syncope (fainting) can occur in association with administration of injectable vaccines, including FLUCELVAX QUADRIVALENT. Syncope can be accompanied by transient neurological signs such as visual disturbance, paresthesia, and tonic-clonic limb movements. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope by maintaining a supine or Trendelenburg position.

After vaccination with FLUCELVAX QUADRIVALENT, immunocompromised individuals, including those receiving immunosuppressive therapy, may have a reduced immune response.

Vaccination with FLUCELVAX QUADRIVALENT may not protect all vaccine recipients against influenza disease.

ADVERSE REACTIONS

In children 6 months through 3 years of age who received FLUCELVAX QUADRIVALENT, the most commonly reported injection-site adverse reactions were tenderness (27.9%), erythema (25.8%), induration (17.3%) and ecchymosis (10.7%). The most common systemic adverse reactions were irritability (27.9%), sleepiness (26.9%), diarrhea (17.9%) and change of eating habits (17.4%).

In children 2 through 8 years of age who received FLUCELVAX QUADRIVALENT, the most commonly reported injection-site adverse reactions were tenderness (28.7%), pain (27.9%) and erythema (21.3%), induration (14.9%) and ecchymosis (10.0%). The most common systemic adverse reactions were sleepiness (14.9%), headache (13.8%), fatigue (13.8%), irritability (13.8%) and loss of appetite (10.6%).

In children and adolescents 9 through 17 years of age who received FLUCELVAX QUADRIVALENT, the most commonly reported injection-site adverse reactions were injection site pain (21.7%), erythema (17.2%) and induration (10.5%). The most common systemic adverse reactions were headache (18.1%) and fatigue (17.0%).

In adults 18 through 64 years of age who received FLUCELVAX QUADRIVALENT, the most commonly reported injection-site adverse reactions were pain (45.4%), erythema (13.4%) and induration (11.6%). The most common systemic adverse reactions were headache (18.7%), fatigue (17.8%) and myalgia (15.4%).

In adults ≥65 years of age who received FLUCELVAX QUADRIVALENT, the most commonly reported injection-site adverse reactions were pain (21.6%) and erythema (11.9%).

Other adverse events may occur.

To report SUSPECTED ADVERSE REACTIONS, contact CSL Seqirus at 1-855-358-8966 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

Before administration, please see the full US Prescribing Information for FLUCELVAX QUADRIVALENT [here](#).

FLUCELVAX® QUADRIVALENT is a registered trademark of Seqirus UK Limited or its affiliates.

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION AND USAGE

AFLURIA QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. AFLURIA QUADRIVALENT is approved for use in individuals 6 months of age and older.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine.

WARNINGS AND PRECAUTIONS

If Guillain-Barré Syndrome (GBS) has occurred within 6 weeks of previous influenza vaccination, the decision to give AFLURIA QUADRIVALENT should be based on careful consideration of the potential benefits and risks.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.

Immunocompromised persons may have a diminished immune response to AFLURIA QUADRIVALENT.

Vaccination with AFLURIA QUADRIVALENT may not protect all individuals.

ADVERSE REACTIONS

AFLURIA QUADRIVALENT administered by needle and syringe:

In children 6 months through 35 months of age, the most frequently reported injection site reactions in the clinical study with AFLURIA QUADRIVALENT administered by needle and syringe were pain and redness ($\geq 20\%$). The most common systemic adverse events were irritability ($\geq 30\%$), diarrhea and loss of appetite ($\geq 20\%$).

In children 36 through 59 months of age, the most commonly reported injection site reactions in the clinical study with AFLURIA QUADRIVALENT administered by needle and syringe were pain ($\geq 30\%$) and redness ($\geq 20\%$). The most commonly reported systemic adverse events were malaise and fatigue, and diarrhea ($\geq 10\%$).

In children 5 through 8 years, the most commonly reported injection-site adverse reactions when AFLURIA QUADRIVALENT was administered by needle and syringe

were pain ($\geq 50\%$), redness and swelling ($\geq 10\%$). The most common systemic adverse event was headache ($\geq 10\%$).

In children 9 through 17 years, the most commonly reported injection-site adverse reactions when AFLURIA QUADRIVALENT was administered by needle and syringe were pain ($\geq 50\%$), redness and swelling ($\geq 10\%$). The most common systemic adverse events were headache, myalgia, and malaise and fatigue ($\geq 10\%$).

In adults 18 through 64 years of age, the most commonly reported injection-site adverse reaction observed in clinical studies with AFLURIA QUADRIVALENT administered by needle and syringe was pain ($\geq 40\%$). The most common systemic adverse events observed were myalgia and headache ($\geq 20\%$).

In adults 65 years of age and older, the most commonly reported injection-site adverse reaction observed in clinical studies with AFLURIA QUADRIVALENT administered by needle and syringe was pain ($\geq 20\%$). The most common systemic adverse event observed was myalgia ($\geq 10\%$).

AFLURIA (trivalent formulation) administered by PharmaJet Stratis Needle-Free Injection System:

The safety experience with AFLURIA (trivalent formulation) is relevant to AFLURIA QUADRIVALENT because both vaccines are manufactured using the same process and have overlapping compositions.

In adults 18 through 64 years of age, the most commonly reported injection-site adverse reactions observed in a clinical study with AFLURIA (trivalent formulation) using the PharmaJet Stratis Needle-Free Injection System were tenderness ($\geq 80\%$), swelling, pain, redness ($\geq 60\%$), itching ($\geq 20\%$) and bruising ($\geq 10\%$). The most common systemic adverse events were myalgia, malaise ($\geq 30\%$) and headache ($\geq 20\%$).

Other adverse events may occur.

To report SUSPECTED ADVERSE REACTIONS, contact CSL Seqirus USA Inc. at 1-855-358-8966 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

Before administration, please see the full Prescribing Information for AFLURIA QUADRIVALENT [here](#).

AFLURIA® and AFLURIA® QUADRIVALENT are registered trademark of Seqirus UK Limited or its affiliates.

PharmaJet® and STRATIS® are registered trademarks of PharmaJet.

Information on reimbursement is provided as a courtesy. Due to the rapidly changing nature of the law, Medicare payment policy, and/or reliance on information provided by outside sources, the information provided herein does not constitute a guarantee or warranty that reimbursement will be received or that the codes identified herein are or will remain applicable. This information is provided “as is” and without any other warranty or guarantee, expressed or implied, as to completeness or accuracy, or otherwise.

Providers must confirm or clarify coding and coverage from their respective payers, and are responsible for accurate reporting of products in accordance with particular payer requirements.

References: **1.** Centers for Disease Control and Prevention. CPT codes mapped to CVX codes. Accessed February 6, 2023. <https://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cpt> **2.** FLUAD QUADRIVALENT. Package insert. Seqirus Inc. **3.** FLUCELVAX QUADRIVALENT. Package insert. Seqirus Inc. **4.** American Academy of Pediatrics. Coding for pediatric preventive care 2022. Accessed February 6, 2023. <https://downloads.aap.org/AAP/PDF/Coding%20Preventive%20Care.pdf> **5.** Centers for Medicare & Medicaid Services. Flu shot & administration. Accessed February 6, 2023. <https://www.cms.gov/Medicare/Prevention/PrevntionGenInfo/medicare-preventive-services/MPS-QuickReferenceChart-1.html#FLU> **6.** American Medical Association. Current Procedural Terminology 2023 (Professional Edition). American Medical Association; 2022. **7.** Centers for Medicare & Medicaid Services. ICD-10-CM tabular list of diseases and injuries. Accessed February 6, 2023. <https://www.cms.gov/medicare/icd-10/2021-icd-10-cm> **8.** AFLURIA QUADRIVALENT. Package insert. Seqirus Inc. **9.** Centers for Disease Control and Prevention. ACIP Flu Meeting Update: Flu vaccines worked better than reported & ACIP recommends specific vaccines for seniors. Accessed February 6, 2023. <https://www.cdc.gov/flu/spotlights/2021-2022/specific-vaccines-seniors.htm> **10.** Centers for Medicare & Medicaid Services. Seasonal influenza vaccines pricing. Accessed February 6, 2023. <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/VaccinesPricing> **11.** Centers for Medicare & Medicaid Services. Physician Fee Schedule. Accessed February 6, 2023. <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched> **12.** National Council for Prescription Drug Programs. Telecommunication version D and above questions, answers and editorial updates version 52. Accessed February 6, 2023. <https://www.ncdp.org/NCPDP/media/pdf/VersionD-Questions.pdf>

flu360[®] pairs our portfolio of innovative influenza vaccines with the support you need



3 easy ordering methods:



Order online at flu360.com



Email customer service at customerservice.us@seqirus.com



Contact your CSL Seqirus account manager about our portfolio of influenza vaccines and treatment

Questions?



Call flu360 Customer Service
(855) 358-8966, option 2